Harrow, Inc. · NASDAQ:HROW
Harrow — Investor Presentation (November 2025)
37 slides from Harrow's investor presentation, Nov 10, 2025
Slide 1: Corporate Presentation November 2025
Corporate Presentation November 2025 >» HARROW Your patients. Our purpose.
Slide 2: Safe Harbor
Safe Harbor This presentation contains “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptio
Slide 3: Largest U.S. portfolio of ophthalmic products
Largest U.S. portfolio of ophthalmic products broadly covering the ophthalmic anatomy Harrow — A Leading Provider of Ophthalmic Disease Management Solutions in North America Key revenve drivers are best- in-class products with large market opportunities Scalable commercial platform with an innovativ
Slide 4: Harrow's Ophthalmic Disease Management Solutions
Harrow’s Ophthalmic Disease Management Solutions DRY EYE RETINA IHEEZO. ict tc vows FRESHKOTE™ ei ‘pate sp) im Flarex’ een hase ©@Byooviz" “ptoartyae) ‘temic * TRIESENCE is sold by the Retina Team, primarily for visualization during vitrectomy, and by the Surgical Team, primarily for controling ocul
Slide 5: Investment Highlights
ooo ese Investment Highlights Recent Launches and 2025-2028 Pipeline Accelerating Growth Trajectory Rare & Specialty Products Large market; + 20% growth in + 67% growth in unit High margin and category-leading revenue in @3 2025 demand @3 2025 vs stable workhorse potential; 22% vs Q2 2025 2 2025 pro
Slide 6: Our Vision is to Become the Next Great US Ophthalmic Company
Our Vision is to Become the Next Great US Ophthalmic Company y + “Harrow was founded in 2012 with $1 million of capital and $1 trillion of determination” ... Mark L. Baum + Founders lead all business development activities, supported by Harrow SMES 1ed; fast-moving and dynamic; seize ground and adap
Slide 7: Financials and Commercial Overview
Financials and Commercial Overview ‘Corporate Presentation | November 2025 HARROW’
Slide 8: Q3 2025 Key Financial Metrics
Q3 2025 Key Financial Metrics (in inousanay Consolidated Revenues ‘25 Guidance 1g expenses sted to remain stable $270,000 - $280,000 $199,614 $130,193 $88,595 Teels Sv QUA $72,476 $48,871 20 21 22 23 24 25 Adjusted EBITDA 20 siia7e 513017 21 22 23 $74,290 in cash and cash equivalents as of September
Slide 9: Q3 2025 Key Growth Drivers
Q3 2025 Key Growth Drivers vévye" THEEZO. __ Seeciatty EE imprimis bat nl (Gioopocane HCcphihamcge)35 =» Branded ‘ete $21.5M $5.2M $1.0M $20.5M $18.6M $18.3M $5.2M $21.5M. $22.6M. $21.9M $6.9M $20.1M ons Ee ee ee SCO. $270M - $260M | ead a Soe Sock ae fessional switch volume in Q4 demand Peaercinbus
Slide 10: Commercial Overview
Commercial Overview Market Segment —— Prevalence Aim Mkt Penetration Commercial Priorities c Et folio of Drive increased depth & e Dry Eye 16-20M! pe < Sara LOE! | breadth; leverage new yoyo seliitens preferred coverage 29-30? Pan-retina | | Strategic account activation Leverage injectable and . . t
Slide 11: Addressing Dry Eye Disease
Addressing Dry Eye Disease Corporate Presentation | November 2025,
Slide 12: Addressing Dry Eye Disease
Nese ese Addressing Dry Eye Disease vavye ~ Flarex’ FRESHKOTE® (cyclosporine ophthalmic (Huovometholone acetate solution) 0796 aphthenie suspension} 0. WUBRICANTYE DROPS FDA-approved to treat the signs FDA-approved for use in the Patented through 2039, & symptoms of Dry Eye Disease treatment of ster
Slide 13: VEVYE - A Best-in-Class Solution for Dry Eye Disease
VEVYE - A Best-in-Class Solution for Dry Eye Disease The first and only water-free cyclosporine to treat the signs and symptoms of dry eye disease + Inapre-clinical ex-vivo corneal penetration study, VEVYE's vehicle delivered ~22x more cyclosporine into the cornea than Restasis + Rapid Onset - faste
Slide 14: VEVYE Q3 2025 Key Metrics
ee eee VEVYE Q3 2025 Key Meirics VEVYE Quarterly Revenue Sustained Momentu i enue in 3 2025 vs Q2 2 $22,600,000 QB 2025 vs Q2 2025 sursonano >in g $18,600,000 FOINR $15,962,000 " 22% Growth Q3-25 vs. Q2-25 commercial cover ; sary 1, n $5,186,000 y a ‘4 VAFA The compounding impact of NRx & high refil
Slide 15: VEVYE Outlook
i VEVYE Outlook Dry Eye Disease Branded & Generic TRx ('24-'25) IQVIA Xponent Plantrak weekly data and PhilRx data, week ending 9/26/25 GOALS 2024 2025 Pisw ci3w (€hg% 4 120,000 Branded 400,000 1,208 1,341k | 411% 80,000 60,000 40,000 Generic ey 20,000 ° Jan Mar May Jul Sep Nov Jan Mar May Jul Sep V
Slide 16: Retina (Anesthetics, Therapeutics)
Retina (Anesthetics, Therapeutics) Corporate Presentation | November 2025,
Slide 17: IHEEZO Overview
IHEEZO Overview Sterile, single-patient-use, physician-administered, ophthalmic gel preparation for ocular surface anesthesia, approved by the FDA in ‘September 2022 IHEEZO clinical studies THEEZO (clerogrcaine HO opthatic gt 3% First approved use in the U.S. ophthalmic market of chloroprocaine hydr
Slide 18: IHEEZO Q3 2025 Key Metrics
IHEEZO Q3 2025 Key Metrics Q3 Highlights: * Nearly half (46%) of accounts ordering YTD are new ners * Majority of new accounts were retina practices + Agreements with all 4 major GPOs in retin + 85 omer reorder rate Priorities eadth & dep’ it retina * Drive trial + Explore optio exp via impro IHEEZO
Slide 19: TRIESENCE
ll . TRIESENCE ia amin atntettle syenin) Anyi Description: Q3 Highlights: + The only FDA-approved preservative-free synthetic “Ax growth ferconch corlicosteroid with separate reimbursement in all a - traditional settings of care * 67% volume growth 30 v: Supply Chain: * 53% of all Q3 accounts are ne
Slide 20: Best-in-Class anti-VEGF Biosimilars
Best-in-Class anti-VEGF Biosimilars Recently entered into an agreement with Samsung Bioepis to acquire U.S. commercials rights to portfolio of ophthalmic biosimilars, including BYOOVIZ® (Lucentis Biosimilar) and OPUVIZ™ (Eylea Biosimilar) © F ©Byooviz~ OPUVIZ™ “Slosmt injection Genie) BYOOVIZ (ranib
Slide 21: U.S. Ophthalmic Market Share - Anti-VEGFs
a U.S. Ophthalmic Market Share-Anti- VEGF’s ~8.5M Units Across All Products BYOOVIZ (Lucentis) & OPUVIZ (Eylea) offer a Unit Volume’ compelling value proposition and cost-effective alternative to current Anti- VEGF therapies & 2,550,000 2,550,000 compounded Avastin: + An FDA-approved, clinically-val
Slide 22: Rare & Specialty Product Portfolio
Rare & Specialty Product Portfolio Corporate Presentation | November 2025
Slide 23: Rare & Specialty Product Portfolio
Rare & Specialty Product Portfolio “Workhorse” products in U.S. optometry and ophthalmology offices Steroids, NSAIDs, and Antihistamine, Antibiotics, and Anti-inflammatories Antibiotic + Steroid Combination Ca (coaiay New commercial leadership to over penn 0 hal portfolio of products = Gass program
Slide 24: Surgical
Surgical ‘Corporate Presentation | November 2025 HARROW’
Slide 25: Ocular Surgery Introduction
Ocular Surgery Introduction AMBITION juniti US Ocular Surgery Volume (‘000) Harrow intelligence, "All Other" includes Retinal Surgery, Strabismus/Eye Muscle Surgery, Oculoplastic Surgery Cataracts 4,500 Glaucoma 4,700 ~500k steroid injections (est) ~4M use topical steroids Refractive 850 (est) Corne
Slide 26: Building a World-Class Surgical Portfolio
Building a World-Class Surgical Portfolio Best-in-Class Anti-Inflammatories oe (tiaminolon acetonide injectable suspension) 40 mg/ml BYQLOVI" (clobetaso! propionate ‘ophthalmic suspension) 0.05% Establish TRIESENCE as a first- line treatment preservative- free, injectable, and titratable option for
Slide 27: Focusing on the Ocular Inflammation Market
Focusing on the Ocular Inflammation Market Mniesenc (tiameinoloneaetnite injectate suspension ‘mg. INCE as a first-line treatment option for ocular to topical steroids Encouraging physician feedback and early market traction — initial utilization trends indicate strong reception of TRIESENCE in the
Slide 28: BYQLOVI - Best-in-Class Steroid
Mewiewioo i BYQLOVI - Best-in-Class Steroid BYQLOVI" (clobetasol propionate Recent acquisition leveraging Harrow’s ophthalmic suspension) 0.05% commercial infrastructure Description: + BYQLOVI is an FDA-approved steroid to treat inflammation and pain after ocular surgery + Super potent and unique st
Slide 29: MELT-300: IV- and Opioid-Free Procedural Sedation
MELT-300: IV- and Opioid-Free Procedural Sedation Fixed dose sublingual tablet combining 3 mg midazolam + 50 mg ketamine (non-opioid), two known and proven FDA-approved molecules in a novel form Technology + Dissolves in seconds under the tongue, using proprietary Zydis® manufacturing technology exc
Slide 30: Next Steps For MELT-300
NG ese Next Steps For MELT-300 Agreement with U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment* (SPA) for the MELT-300 Phase 3 Study Covering: @ Study Design and Planned Analysis i @ Study Statistical Approach Anti @ Primary and Secondary Endpoints N FDA agreed that the Phase
Slide 31: Ensuring Access and Affordability
Ensuring Access, and Affordability Corporate Presentation | November 2025
Slide 32: VEVYE Access For All (VAFA)
VEVYE Access For All (VAFA) Predictable Patient Experience: VEVYE is dispensed, regardless of insurance coverage, for $0-$59 per bottle'=* Specialty pharmacy partner adjudicates Rx and dispenses VEVYE Eyecare professional prescribes through EMR + Remove Barriers to Access for Patients and Providers
Slide 33: Harrow Access For All (HAFA)
— Harrow Access For All (HAFA) Building on the Success of VEVYE Access for All Available Through a Single Harrow Portfolio ——- Branded Products (Q42025) [i Compounded (2027) 4 Trusted Access Point Accessible and Affordable for All Patients ‘The Amazon for Ophthalmology’ A seamless and unified platfo
Slide 34: Commitment to Supporting Mission Trips
Commitment to Supporting Mission Trips See Intl Eye Doctors of Lancaster Nevis Eye Care Health in Sight Missions (Honduras) April 2024 (Africa) October 2024 (West Indies) November 2024 (Honduras) February 2025 During We are proud to have never turned down an opportunity to provide Harrow products to
Slide 35: Compounded Products
Compounded Products Corporate Presentation | November 2025
Slide 36: ImprimisRx
ImprimisRx + Leading U.S. ophthalmic-focused compounding business * More than 15,000 U.S. customers + 50-state dispensing capabilities + Broad product portfolio with a concentration on supporting surgical interventions + Through "Project Beagle,” Harrow is transitioning patients from compounded prod
Slide 37: HARROW
>» HARROW Your patients. Our purpose. 1A Burton Hills Blvd., Suite 200 Nashville, Tennessee 37215 Harrow.com Mike Biega Vice President of Investor Relations & Communicatio: mbiega@harrowinc.com Your patients. Our purpose. Direct: 617-913-8890 Corporate Presentation HARROW